Theory Paper IIDrNB Cardiology – Theory Notes
ANTI-INFLAMMATORY THERAPIES IN SECONDARY PREVENTION OF ASCVD
IRATIONALE (THE INFLAMMATORY HYPOTHESIS OF ATHEROTHROMBOSIS)
- Residual Inflammatory Risk: A substantial proportion of patients with established Atherosclerotic Cardiovascular Disease (ASCVD) experience recurrent Major Adverse Cardiovascular Events (MACE) despite achieving guideline-mandated LDL-C targets; this residual risk is driven by the canonical NLRP3 Inflammasome – Interleukin-1beta (IL-1b) – Interleukin-6 (IL-6) – C-Reactive Protein (hs-CRP) innate immunity signaling axis.
- Pathophysiological Mechanism: Cholesterol crystals, oxidized LDL, and disturbed shear stress activate the intraplaque macrophage NLRP3 inflammasome, stimulating matrix metalloproteinase secretion, collagen degradation, thinning of the protective fibrous cap, and acute plaque rupture or erosion.
IICOLCHICINE (THE TARGETED TUBULIN / NLRP3 INHIBITOR)
- Mechanism of Action: Binds tubulin heterodimers to inhibit microtubule polymerization, thereby blocking NLRP3 inflammasome assembly, neutrophil chemotaxis/degranulation, and platelet-leukocyte aggregation, reducing downstream IL-1beta, IL-18, IL-6, and hs-CRP.
- Landmark Clinical Trials:
- COLCOT Trial (NEJM 2019 — Early Post-MI): In patients randomized within 30 days of an acute myocardial infarction, low-dose Colchicine (0.5 mg once daily) reduced the primary composite endpoint of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization by 23 percent.
- LoDoCo2 Trial (NEJM 2020 — Chronic Coronary Syndrome): In patients with stable chronic coronary disease on optimal lipid-lowering therapy, Colchicine 0.5 mg daily reduced the primary composite of CV death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization by 31 percent.
- CLEAR SYNERGY (OASIS-9) Trial (NEJM 2024 — Acute MI Undergoing PCI): In 7,062 patients initiated immediately after acute MI treated with PCI, Colchicine 0.5 mg daily showed no reduction in MACE at 3 years despite lowering CRP, tempering routine acute post-MI initiation while supporting selective use in chronic stable ASCVD with persistent inflammatory risk.
- Guideline Status (2024 ESC Chronic Coronary Syndromes Guidelines): Upgraded to a Class IIa (Level A) recommendation: low-dose Colchicine (0.5 mg once daily) should be considered in patients with atherosclerotic CAD to reduce MI, stroke, and need for revascularization, particularly when residual inflammatory risk (hs-CRP greater than 2.0 mg/L) or recurrent events persist despite optimal statin/lipid therapy (avoiding use in severe CKD or concurrent strong CYP3A4/P-gp inhibitors).
IIICANAKINUMAB (PROOF OF CONCEPT FOR THE IL-1BETA PATHWAY)
- Mechanism of Action: Fully human monoclonal antibody that selectively binds and neutralizes circulating Interleukin-1beta (IL-1b).
- Landmark Trial — CANTOS (NEJM 2017): Randomized 10,061 patients with prior myocardial infarction and persistent hs-CRP of 2.0 mg/L or greater to subcutaneous Canakinumab versus placebo. The 150 mg dose reduced recurrent MACE by 15 percent with zero change in LDL-C, providing the first definitive proof of the inflammatory hypothesis of human atherosclerosis.
- Clinical Status: Not approved or used in routine cardiovascular practice due to high cost and a small but statistically significant increase in fatal infection/sepsis, though it established the IL-1b/IL-6 pathway as a validated therapeutic target.
| Anti-Inflammatory Agent | Molecular Target | Landmark Trial(s) | Primary MACE Outcome & Clinical Status |
|---|---|---|---|
| Colchicine (0.5 mg OD) | Tubulin / NLRP3 inflammasome & neutrophil function | COLCOT (2019), LoDoCo2 (2020), CLEAR SYNERGY (2024) | 23% RRR in COLCOT; 31% RRR in LoDoCo2 (neutral in acute MI in CLEAR SYNERGY); ESC 2024 Class IIa in CCS |
| Canakinumab | Monoclonal antibody against IL-1beta | CANTOS (NEJM 2017) | 15% RRR in MACE independent of LDL-C; proof-of-concept, not used clinically due to cost & fatal infection risk |
| Low-Dose Methotrexate | Dihydrofolate reductase / adenosine purine pathway | CIRT (2019) | Neutral (0% reduction in MACE) and did not lower IL-1b, IL-6, or hs-CRP; not recommended |
| Ziltivekimab | Monoclonal antibody against IL-6 ligand | RESCUE (Phase II); ZEUS / HERMES (Phase III) | Lowered hs-CRP by ~80–90% in RESCUE; Phase III ZEUS missed primary MACE endpoint and HERMES halted for futility in Sept 2026 |
IVMETHOTREXATE (THE FAILED BROAD IMMUNOSUPPRESSANT)
- Mechanism and Landmark Trial (CIRT): Low-dose Methotrexate (15 to 20 mg weekly) was evaluated in the Cardiovascular Inflammation Reduction Trial (CIRT) in patients with prior MI/multivessel CAD and diabetes or metabolic syndrome.
- Key Lesson: Methotrexate failed to reduce IL-1beta, IL-6, or hs-CRP levels and had zero effect on MACE, proving that atheroprotection requires specific inhibition of the canonical NLRP3–IL-1b–IL-6 pathway rather than non-specific immunosuppression.
VZILTIVEKIMAB AND DIRECT INTERLEUKIN-6 TARGETING
- Mechanism and Phase II Evidence: Ziltivekimab is a fully human monoclonal antibody directed against the Interleukin-6 (IL-6) ligand. In the Phase II RESCUE Trial, Ziltivekimab produced dose-dependent 77 to 92 percent reductions in hs-CRP, fibrinogen, serum amyloid A, and lipoprotein(a) in patients with moderate-to-severe CKD.
- Phase III Outcomes Update (ZEUS and HERMES Trials, 2026): Although Phase III trials (ZEUS in atherosclerotic CKD with hs-CRP >=2 mg/L and HERMES in HFmrEF/HFpEF) were launched to test whether direct IL-6 inhibition reduces MACE, topline results in 2026 showed that ZEUS missed its primary MACE endpoint and HERMES was subsequently halted early for futility, leaving low-dose Colchicine and high-intensity Statins (JUPITER Trial) as the only clinically established oral anti-inflammatory therapies in ASCVD.
VICLINICAL SUMMARY ALGORITHM FOR SECONDARY PREVENTION
- Dual-Target Assessment (“Residual Cholesterol Risk” vs. “Residual Inflammatory Risk”): In patients with established ASCVD on maximally tolerated high-intensity statin + ezetimibe (+/- PCSK9 inhibitor or bempedoic acid):
- If LDL-C remains >=55 mg/dL (or ApoB >=65 mg/dL): Intensify lipid-lowering therapy (Ezetimibe, PCSK9 mAb/Inclisiran, or Bempedoic Acid).
- If LDL-C is at goal (<55 mg/dL) but hs-CRP remains persistently >=2.0 mg/L (or recurrent ischemic events occur): Consider adding Low-Dose Colchicine 0.5 mg once daily (ESC 2024 Class IIa).
Key references
- Ridker PM, Everett BM, Thuren T, et al. (CANTOS Trial Group): Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, New England Journal of Medicine, 2017.
- Vrints C, Andreotti F, Koskinas KC, et al.: 2024 ESC Guidelines for the management of chronic coronary syndromes, European Heart Journal, 2024.
- Jolly SS, d’Entremont MA, Lee SF, et al. (CLEAR SYNERGY OASIS 9 Investigators): Colchicine in Acute Myocardial Infarction, New England Journal of Medicine, 2024.
meritmedscript.comDr. Sidhartha Mullapudi
